Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus (COVID-19) Vaccine
16 avr. 2020 07h30 HE
|
Dynavax Technologies Corporation
The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate EMERYVILLE,...
Dynavax Donates 10,000 Doses of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Vaccine to Emergency Healthcare Providers and Hospital Staff to Protect Against Hepatitis B Infections Amidst COVID-19 Pandemic
08 avr. 2020 08h00 HE
|
Dynavax Technologies Corporation
The U.S. FDA approved vaccine is being provided to help protect critical healthcare workers in emergency medical settings from hepatitis B infections EMERYVILLE, Calif., April 08, 2020 (GLOBE...
Dynavax Provides Business Update on COVID-19 Pandemic Impact
02 avr. 2020 16h30 HE
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)
26 mars 2020 07h30 HE
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the...
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
24 mars 2020 08h30 HE
|
Dynavax Technologies Corporation
Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccineClover advancing evaluation of its...
Dynavax Announces Fourth Quarter and Full Year 2019 Financial Results
11 mars 2020 16h10 HE
|
Dynavax Technologies Corporation
Full year 2019 HEPLISAV-B® net product revenue of $34.6 million, in line with upwardly-revised guidanceAim to grow 2020 HEPLISAV-B® net product revenue by approximately 70 percent over 2019Advancing...
Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine
02 mars 2020 08h00 HE
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11
24 févr. 2020 16h05 HE
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will...
Dynavax to Present at the Cowen 40th Annual Health Care Conference
18 févr. 2020 16h05 HE
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors
16 déc. 2019 16h15 HE
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...